|
|
 |
|
Viewing report
|
|
|
|
Kidney Cancer Drugs - Global Strategic Business Report
Global Industry Analysts, Inc, Aug 2011, Pages: 260
This report analyzes the worldwide markets for Kidney Cancer Drugs in US$ Million. This report on ‘Kidney Cancer Drugs' provides market analytics specifically for the “Renal Cell Carcinoma” (RCC) market, owing to its predominance among the various types of kidney cancers. The market for Renal Cell Carcinoma (RCC) drugs is analyzed by the two major drug classes, which include: Multikinase Inhibitors, and Other RCC drug Classes (including Immunomodulators; mTOR inhibitors; and other emerging drug classes). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2008 through 2017.
The report profiles 19 companies including many key and niche players such as
- AVEO Pharmaceuticals (US)
- AstraZeneca Plc. (UK)
- Bayer Schering Pharma AG (Germany)
- Bristol-Myers Squibb Co. (US)
- Onyx Pharmaceuticals, Inc. (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- GlaxoSmithKline Plc. (UK)
- Merck-Serono (Switzerland)
- Novartis AG (Switzerland)
- Pfizer, Inc. (US)
- WILEX AG (Germany)
Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.
For information on site licence pricing please click on Enquire before buying
|
|
|
|
